Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab in recurrent ovarian cancer
NCT00073541Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Apr 2003
- Primary completion
- Mar 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of matuzumab in ovarian cancer, sponsored by EMD Serono. Primary endpoint: Objective Response Rate. Started Apr 2003; status: completed.
02
Drugs
matuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00073541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073541.